Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vasopressin · 1 trial · 2 indications
all cause mortality within 30 days
| Arm | Type | Description |
|---|---|---|
| Prehospital Intervention Arm | EXPERIMENTAL | 1 gram calcium gluconate provided via intravenous or intraosseous access over approximately 2-5 minutes, initiated prior to trauma bay arrival and infused to completion following arrival if needed |
| Prehospital Control Arm | PLACEBO_COMPARATOR | Identical volume saline placebo to prehospital intervention arm provided via intravenous or intraosseous access over approximately 2-5 minutes, initiated prior to trauma bay arrival and infused to completion following arrival if needed |
| Early In-Hospital Intervention Arm | EXPERIMENTAL | 4-unit vasopressin bolus followed by a vasopressin infusion at 0.04 U/min for 8 hours. Administration of the bolus will be initiated as soon as feasible and within approximately 2 hours of enrollment. The infusion will be initiated within approximately 30 minutes of the bolus. |
| Early In-Hospital Control Arm | PLACEBO_COMPARATOR | volume matched saline bolus followed by volume matched normal saline placebo infusion for eight hours initiated within approximately two hours of enrollment |
| Name | Type | Description |
|---|---|---|
| Calcium Gluconate | DRUG | 1 gram calcium gluconate provided via intravenous or intraosseous access over approximately 2-5 minutes |
| Vasopressin | DRUG | 4 unit vasopressin bolus followed by vasopressin infusion at 0.04 U/min for eight hours |
| saline placebo | DRUG | saline placebo volume matched to prehospital or in hospital phase |
Inclusion Criteria: Prehospital Phase: Injured patients at risk of hemorrhagic shock being transported from scene or referral hospital to a participating CAVALIER trial site who meet the following criteria: 1A. Systolic blood pressure ≤ 90mmHg and tachycardia (HR ≥ 108) at scene, at outside hospi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| CytoSorbents Corporation | CTSO | 1 | - | Undisclosed |
| Bone Biologics Corp. | BBLG | 1 | - | Undisclosed |
Vasopressin is an investigational small molecule being studied for use in trauma and hemorrhage. It is currently in Phase 2 clinical development, evaluated in the CAVALIER trial for early resuscitation following injury. The drug is being developed by United Therapeutics Corporation.
Vasopressin is a small molecule that acts as a vasopressor, helping to constrict blood vessels and raise blood pressure. In the context of trauma and hemorrhage, it is being studied to support resuscitation efforts. The drug is being developed by United Therapeutics Corporation.
Vasopressin is being developed by United Therapeutics Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker UTHR. The company is conducting a Phase 2 clinical trial of Vasopressin for trauma and hemorrhage.
Vasopressin is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 2 trial, NCT05958342, is currently recruiting participants in the United States.
Vasopressin is being evaluated in one active Phase 2 clinical trial, NCT05958342, titled 'CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial'. This randomized, double-blind, placebo-controlled study is recruiting 1,050 participants aged 18 years and older with trauma and hemorrhage.
Vasopressin is also known by its chemical name, arginine vasopressin, and is sometimes referred to as antidiuretic hormone (ADH). In the context of this clinical development program, it is being studied under the name Vasopressin by United Therapeutics Corporation.